The Online Investor
Cubist Pharmaceuticals Inc. (CBST)

Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat patients who are hospitalized or are being treated in other acute care settings. Co. has three marketed products: CUBICIN® for the treatment of certain Gram-positive bacteria and for certain bloodstream infections; DIFICID® for the treatment of Clostridium difficile-associated diarrhea (CDAD); and ENTEREG® to accelerate gastrointestinal recovery. Co. has four late-stage product candidates: Tedizolid phosphate and Ceftolozane/tazobactam for treatment of Gram-positive bacterial infections; Surotomycin for CDAD; and Bevenopran for opioid-induced constipation.
Company Name: 
Cubist Pharmaceuticals Inc.
Quotes delayed 20 minutes

Email EnvelopeFree CBST Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (1.96 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Cubist Pharmaceuticals Inc. (CBST) Page | The Online Investor Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.